A hyperinflammation clinical risk tool, HI5-NEWS2, stratifies hospitalised COVID-19 patients to associate risk of death and effect of early dexamethasone in an observational cohort

BACKGROUND: The success of early dexamethasone therapy for hospitalised COVID-19 cases in treatment of Sars-CoV-2 infection may predominantly reflect its anti-inflammatory action against a hyperinflammation (HI) response. It is likely that there is substantial heterogeneity in HI responses in COVID-...

Descripción completa

Detalles Bibliográficos
Autores principales: Ardern-Jones, Michael R., Phan, Hang T. T., Borca, Florina, Stammers, Matt, Batchelor, James, Reading, Isabel C., Fletcher, Sophie V., Smith, Trevor, Duncombe, Andrew S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844906/
https://www.ncbi.nlm.nih.gov/pubmed/36649371
http://dx.doi.org/10.1371/journal.pone.0280079

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9844906/
https://www.ncbi.nlm.nih.gov/pubmed/36649371
http://dx.doi.org/10.1371/journal.pone.0280079

Ejemplares similares